admin

Following the recent presidential election, Bluesky has remarkably positioned itself as a growing competitor in the social media realm, challenging established platforms like Elon Musk’s X (formerly Twitter) and Meta’s Threads. With over 21 million users, although still a fraction of Threads’ 275 million and X’s claimed 600 million, the company is rapidly gaining traction.
0 Comments
Baidu, the prominent Chinese technology firm, recently unveiled its earnings for the third quarter of the fiscal year, illustrating a blend of challenges and advances. The company’s revenue fell by 3% compared to the previous year, totaling approximately $4.78 billion for the quarter ending on September 30. Despite this decline, Baidu exceeded analyst expectations, which
0 Comments
In a noteworthy decision that could signal a trend among corporations, Acurx Pharmaceuticals has recently sanctioned a plan to purchase up to $1 million in Bitcoin. This acquisition is intended to serve as a treasury reserve asset—an intriguing strategy that underscores the evolving landscape of corporate finance. Following the announcement, Acurx’s stock experienced a fluctuation,
0 Comments
As the U.S. economy navigates a complex landscape of inflation and wage dynamics, recent comments from Federal Reserve Governor Lisa Cook provide critical insights into future monetary policy directions. In her recent remarks, Cook emphasized a notable easing of inflationary pressures, linked to a cooling job market and limited price increases predominantly seen in the
0 Comments
Scheduled for release on February 7, 2025, “Bring Them Down” emerges as a promising addition to the MUBI lineup, showcasing a blend of raw emotion and gripping storytelling. Directed by Christopher Andrews in his feature debut, the film stars Barry Keoghan, known for his Oscar-nominated performances, and Christopher Abbott, who embodies the character of Michael—a
0 Comments
Pfizer, the multinational pharma giant, is navigating turbulent waters as it seeks to revitalize its research and development (R&D) efforts following a year marked by investor scrutiny. On Wednesday, the company announced the appointment of Chris Boshoff, the current head of oncology, as its chief of research and development. This strategic move comes amid mounting
0 Comments